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Objectives. The aim of this meta-analysis was to determine the eﬀectiveness of the fermented plant extract Iscador, produced from
the white-berry European mistletoe, in the treatment of patients with cancer with respect to quality-of-life- (QoL-) associated
measures. Methods.We searched databases such as PubMed/Medline, Excerpta Medica Database (EMBASE), CAMbase, and other
for controlled clinical studies on parameters associated with QoL. Outcome data were extracted and converted into standardized
meandiﬀerences and their standard errors. Results. Thirteen prospective and controlled studies which met the inclusion/exclusion
criteria reported positive eﬀects in favor of the Iscador application. A random-eﬀect meta-analysis estimated the overall treatment
eﬀect at standardized mean diﬀerence = 0.56 (CI: 0.41 to 0.71, P<. 0001). However, the methodological quality of the studies
was poor. Conclusions. The analyzed studies give some evidence that Iscador treatment might have beneﬁcial short-time eﬀects on
QoL-associated dimensions and psychosomatic self-regulation.
1.Introduction
Complementary and alternative medicine (CAM) has be-
come increasingly popular over the last decades. According
to Bausell et al., especially patients with chronic diseases
increasingly seek for CAM-therapies [1]. With a growing
amount of health information in the internet, physicians
and therapists and patients are often not prepared to
judge provided information of CAM health care approaches
properly. Information dissemination of published evidence
about the eﬀectiveness of remedies and therapies therefore
forms a necessary basis for shared decision making for
patients and practitioners.
In Europe, extracts from Viscum album (VA-E), the
European white-berry mistletoe, are widely used to treat
patients with cancer, in addition to patients with arthrosis,
hypertension, arteriosclerosis, diabetes, and so forth [2]
Historically, the intentions of mistletoe uses were manifold
and conﬂicting in several cases (i.e., swellings or tumors,
epilepsy, diseases of spleen and liver, labor pains, “weakness
of the heart,” edema, eczema, ulcers of the feet, burns,
and granulating wounds) [2]. In 1920, mistletoe extracts
were introduced for the ﬁrst time as a cancer treatment
by Steiner (1861–1925) [3], the founder of anthroposophy.
He recommended a drug extract produced in a compli-
cated manufacturing process combining sap from mistletoe
harvested in the winter and summer [4]. Based on his
recommendations, several anthroposophical doctors have
treated their cancer patients with these extracts within the
last century.
Meanwhile, clinical evaluations of mistletoe as an adju-
vant cancer treatment have expanded. Recent scientiﬁc
research has conﬁrmed that mistletoe extracts induce
apoptosis, stimulate immunocompetent cells, and protect
the DNA of mononuclear cells (for review see [2, 5, 6]).
Several experiments using tumor-bearing animals showed
impressive reduction of tumor growth and/or increased
survival with the applicationof mistletoe therapy (for review
see [2, 5, 6]). There are several whole-plant extracts from
Viscum album on the market which diﬀer with respect to
the extraction process and thus relative proportions of their
constituents [7]. Due to this diversity of mistletoe products
and their proportions of pharmacologically relevant con-
stituents, the interpretation of clinical studies is diﬃcult.
Consequently it is not too surprising that preceding reviews
on the clinical eﬀects of mistletoe extracts in cancer patients,
which summarizes amixtureofstudieswithdiﬀerentdesigns
and plant extracts used, are conﬂicting in their results [6, 8–
13].Severalofthesereviewsdetectedheterogeneityofstudies
with respect to the drug extracts used to treat the patients2 Evidence-Based Complementary and Alternative Medicine
and thus are not suited to calculate reliable eﬀects sizes. In
fact, there are up to ﬁve diﬀerent pharmaceutical processes
ofmistletoeextractpreparation,andthusthepharmaceutical
products show highly speciﬁc pattern of active components
(i.e., pattern of cytotoxic mistletoe lectins, viscotoxins, etc.)
[7]. To overcome this problem, we intended to determine
the eﬀectiveness of VA-E in the treatment of patients with
cancer and focused on the most commonly used VA-E
which is covered by a relatively large spectrum of published
studies, the fermented plant extract Iscador (WELEDA AG,
Switzerland). This whole-plant extract is produced from
fresh leafy shoots and fruits of the summer and winter
harvest, is rich on mistletoe lectins and viscotoxins [7, 14],
and is recommended to be applied 2-3 times per week
subcutaneously.
While most clinical studies on the eﬀects of VA-E focus
on the survival of cancer patients, the eﬀects on the patients’
qualityoflife(QoL),whichgains moreandmoreimportance
as arelevantoutcomevariable incancer therapy,receivedless
consideration so far. Thus, we determined the eﬀectiveness
of the VA-E Iscador in the treatment of patients with cancer
with respect to QoL-associated dimensions and analyzed the
studies with respect to trials where patients of the control
group received only standard care and no extra treatment.
2.Materialsand Methods
2.1. Search Strategy. Between February and April 2008, we
searched databases such as PubMed/Medline, the Excerpta
MedicaDatabase(EMBASE),theCochrane Library,database
of DIMDI (Deutsches Institut f¨ ur Medizinische Dokumen-
tation und Information), and CAMbase for clinical studies
focusing on QoL-associated measures of cancer patients
using Iscador extracts. Search terms were either “Iscador”
and “study”, “mistletoe” and “study”, and “Viscum” and
“study”. Finally we asked several experts for gray literature
not listed in the above-mentioned databases, checked the
reference lists of relevant articles and authors, and contacted
the manufacturer of the VA-E. We performed an additional
check for new studies in 2010, which did not reveal new
results.
2.2. Selection Criteria. Inclusion criteria were all controlled
clinical studies (at least historic or literature) on parameters
associated with quality of life in cancer patients treated
with the VA-E Iscador, published in English or German
language journals. Neither the experts in the ﬁeld nor the
manufacturer was aware of any other study published in
French, Spanish, Chinese, or other languages. However, one
study from Denmark was published in a Danish journal and
in an English language journal, and thus we referred to both
publications presenting data of the same study. We are not
aware of unpublished studies on the eﬀects of Iscador on
QoL.
We excluded ﬁeld reports, case series, case reports,
studies without a control group, abstracts which proceeded
a full-length publication, translations of already published
manuscripts, double publication of similar data (with the
exception of the presentation of further data), internal
reports, and unpublished manuscripts.
2.3. Analysis of Data. Two review authors independently
assessed trials for inclusion in the review. They took part
in the extraction of data and assessment of methodological
quality and external validity. Disagreements were resolved
by consensus. We graded the methodological quality of the
studies by the following checklist (rater assessment): ade-
quate description of the design (retrospective, prospective,
retrolective, multicenterstudy,etc.),accrual(randomization,
matched pairs, etc.), comparability of groups (controls
and VA-E), description of dropouts, allocation concealment
(analysis of concealed treatment allocation was diﬃcult
because most studies did not provide suﬃcient data to
judge—either there were no stat e m e n t so ri n f o r m a t i o nw a s
at least unclear), description of the intervention (dosage
and duration of VA-E application), description of statisti-
cal analysis, and external validity (representative patients,
relevant therapeutic concepts, generalization of results).
Additionally we referred to the JADAD rating score which
assesses randomization, blinding, and dropouts [15].
The reporting of the results adhered to the MOOSE [16]
and QUOROM [17] guidelines.
2.4. Statistical Analysis. If a trial was found to be eligible,
assessments of its methodological quality were done inde-
pendently by two reviewers (A. B¨ ussing, T. Ostermann) and
recorded on an especially predesigned data form together
with the basic trial data and the extracted results. Allocation
concealment was assessed in accordance with the Cochrane
guidelines [18]:
A = adequate (telephone randomization or using
consecutively numbered, sealed, opaque envelopes);
B = uncertainty about the concealment (method of
concealment is not known);
C =inadequate(e.g.,alternatedays,odd/evendateof
birth, hospital number).
Disagreements on methodological quality ratings were
discussed by both assessors until they reached a consensus.
Data were independently extracted by two persons (A.
B¨ ussing, T. Ostermann) and independently entered into
a data form which was especially designed for trials on
mistletoe by a third person (C. Raak). If the data entries
diﬀered, both reviewers were contacted to recheck the
publications and were forced to come to a consensus, which
could be reached in all cases.
Data on the following details were extracted:
(i) details of the publication (ﬁrst author, country, year,
journal),
(ii) details on the dosage and application of Iscador,
(iii) type, name, dosage and application of the control
therapy/alternative therapies,
(iv) grading and location of cancer,
(v) age and gender distribution of patients,Evidence-Based Complementary and Alternative Medicine 3
(vi) methodological quality of the study (see above),
(vii) outcome(s).
All data were separately analyzed for trials where patients
ofthecontrol groupreceived only standard care and no extra
treatment (or placebo-controlled trials). QoL-associated
outcome data (QoL questionnaires and scales: mean values
and standard deviations, mean/median diﬀerences, eﬀect
estimates and conﬁdence intervals, odds ratios, etc.) were
extracted as they were given in the publication. They were
converted into standardized mean diﬀerences (SMD) and
their standard errors (STE) using standard formulas [18].
Eﬀect sizes <0.5 indicate small eﬀects and >0.8 large eﬀects
[19].
All studies were analysed in a single analysis, regardless
of on what scale the results had originally been measured or
reported.
The association between sample size and trial results was
graphically displayed in funnel plots, by plotting eﬀect sizes
on the horizontal axis (in a logarithmic scale) against their
standard errors, or against the total patient numbers, on the
vertical axis [20]. Funnel plots are adequate instruments to
detect small study size eﬀects, including publication bias. In
the absence of bias, results from small studies should scatter
widelyatthe bottomofthegraph, withthespread narrowing
among larger studies. Publication bias (and also lack of
equipoise) may lead to asymmetrical funnel plots. Moreover,
the asymmetry of the funnel plot was further explored by a
weighted linear regression analysis (metaregression) which
modeled the log SMD as a function of its standard error
[21]. Weights were chosen inversely to the squared standard
error. From this model, the asymmetry coeﬃcient (AC) was
estimated as the slope of the regression line.
Heterogeneitybetweentrials wasassessed bystandard χ2-
tests and the I2 coeﬃcient which measures the percentage of
total variation across studies due to true heterogeneity rather
than chance [22].
Overall estimates of the treatment eﬀect were obtained
from random-eﬀect meta-analysis [23]. Additionally, from
metaregression a predicted SMD was obtained for trials with
a standard error as small as the smallest observed standard
error of all included trials. The extent to which study-level
variables were associated with SMDs was investigated by
ﬁtting multivariable metaregression models. The following
variables were considered: standard error of SMD, tumor
localization(breast,stomach, lung,colon,ovary,corpus,skin
cancer yes/no), randomization (yes/no), and matched-pair
comparison (yes/no)—due to the fact that all matched-pair
studies were from the same source.
3.Results
3.1.SearchResults. Wefound16studiesontheclinicaleﬀects
of Iscador usage on QoL-associated dimensions which were
described in 11 publications (Table 1). Some described data
on diﬀerent sets of patients and/or tumor stages or diﬀerent
designs within the same report. Two randomized trials
controlled Iscador against placebo/alternative treatment (i.e.,
water orvitamin B,resp. [24, 25])and thuswere notenrolled
n = 16
n = 2
n = 1
Controlled studies
n = 13
Randomized
n = 9 n = 4
Alternative/placebo treatment
Controlled studies citing QoL-associated dimensions
Nonrandomized
No results for the control group
Figure 1: Flow diagram of study exclusion.
in the evaluation “Iscador versus no extra treatment.” The
results of these studies are nevertheless presented in Table 1.
Moreover, one study with a historic control, reporting
just the QoL results of the VA-E arm [35], was excluded
from the analysis. Thus, 13 studies provided data on QoL
associated dimensions to extract SMDs and their standard
deviations with respect to a comparison Iscador versus no
extra treatment (Figure 1).
3.2. Design of Studies. All of the remaining 13 studies
according to speciﬁcations in the articles had a prospective
design. Nine ofthemwere randomized (Figure 1). According
t ot h en a t u r eo ft h ec o n t r o lg r o u p ,n ot r i a lw a sb l i n d e d .
The oldest study (which was excluded from the analysis
because of a lacking control group) dated back to 1984; all
others were published in 2001 or later, the most recent being
2008. The number of patients enrolled varied considerably
from 32 to 396; overall 734 patients were treated with Iscador
and 741 patients served as controls. In most cases, the
respective dosage of Iscador, was not given in the original
studies.
The trials included in this meta-analysis were of poor
quality, as indicated by randomization, matched-pair build-
ing, blinding, multicenter, description of dropouts, and so
forth. (Table 1). Nine investigations reached a JADAD score
of 2, ﬁve a score of 1, and one no point (Table 1). Due
to methodological problems, an adequate blinding of VA-E
application (which results in most cases in observable local
reactions at the injection site) is not possible (reviewed in
[10]), and thus the most important diﬀerentiating variable
was in fact randomisation versus nonrandomisation and
thus was used for the multivariable metaregression analysis.
3.3. Eﬀect Sizes. As shown in Figure 2, all studies reported
positive eﬀects in favor of the Iscador application. Variability
of study results was moderate (I2 = 42.1%), but the funnel4 Evidence-Based Complementary and Alternative Medicine
Table 1: Overview on identiﬁed clinical studies/strata.
Ref. Year Number of patients Tumor
localization
Study design of all studies
QoL instrument
Outcome
Iscador Control control design matching JADAD score SMD STE
[24]∗ 2001 20 10 Breast PLG Rand — 1 Spitzer QoL
Index
1.71 0.39
[25]∗ 1991 114 113 Lung PLG Rand — 2
Karnofsky’s Index
+ additional
items
0.32 0.15
[26, 27] 2001 39 39 Multiple PLG Rand MP 2 Self regulation 0.53 0.23
[26, 27] 2001 17 17 Breast PLG Rand MP 2 Self regulation 0.53 0.34
[28] 2006 17 17 Breast PLG Rand MP 2 Self regulation 0.67 0.34
[29] 2006 38 38 Breast PLG Rand MP 2 Self regulation 0.53 0.23
[29] 2006 84 84 Breast PLG NR MP 1 Self regulation 0.34 0.15
[30] 2007 41 41 Ovary PLG Rand MP 2 Self regulation 1.24 0.32
[30] 2007 137 137 Ovary PLG NR MP 1 Self regulation 0.45 0.16
[31] 2007 19 19 Cervix PLG Rand MP 2 Self regulation 0.51 0.32
[31] 2007 102 102 Cervix PLG NR MP 1 Self regulation 0.81 0.14
[32] 2007 22 22 Melanoma PLG Rand MP 2 Self regulation 0.84 0.30
[33] 2008 198 198 Corpus uteri PLG NR MP 0 Self regulation 0.27 0.10
[33] 2008 56 56 Corpus uteri PLG Rand MP 1 Self regulation 0.62 0.19
[34] 2005 33 33 Breast PLG Rand — 2 EORTC-QLQ
C30, BR 23
0.59 0.25
[35, 36] 1984 14 — Kidney historic — — — Visualanalogue
Scale
——
PLG: parallel group; Rand: randomization; NR: no randomization; MP: matched pairs; SMD: standardized mean diﬀerences; STE: standard error;
∗placebo/alternative control, and thus not included in the statisticalanalysis.
−10 1 2 3
Standardised mean diﬀerence (SMD)
Figure 2: Standardized treatment eﬀects (SMD and conﬁdence
intervals) of Iscador versus no extra treatment. The size of circles
represents the weight of the study/strata in metaregression.
plot (Figures 3 and 4) showed considerable asymmetry with
the largest investigation revealing the smallest eﬀect (AC =
1.99, CI: 0.20 to 0.52, P<. 0001).
Ar a n d o m - e ﬀect meta-analysis estimated the overall
treatment eﬀe c ta tS M D= 0.56 (CI: 0.41 to 0.71, P<
.0001),indicatingamoderateeﬀect.Inmultivariablemetare-
gression, neither tumor localization nor the design of the
investigation turned out to be signiﬁcantly associated with
better or worse study outcome: breast cancer trials had a
slightly betteroutcome than others(diﬀerence in SMD:0.19,
CI:−0.12to0.50,P = .22),randomizedstudiesdidnotdiﬀer
from nonrandomized (diﬀerence in SMD: −0.05, CI: −0.55
to 0.45, P = .84), and matched-pair studies (which were all
using self regulation as a QoL-associated dimension) were
comparable to others (diﬀerence in SMD: 0.01; CI: −0.55 to
0.45, P = .84).
4.Discussion
4.1. Quality of Studies and Outcome. Although the method-
ological quality of investigations on the clinical eﬀects of
VA-E has improved over the last years, as at least more
randomized controlled studies were performed. However,
many problems still remain: most trials did not report data
on compliance and completeness of follow up, intention-
to-treat analysis was rarely mentioned, and the number of
patients was in all cases <200. Nevertheless, all studies were
prospective and had a parallel group design; most were
randomized, but none was blinded (Table 1). According to
the JADAD score, the methodological quality of the enrolled
investigations to assess the eﬀects of VA-E on patients’Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: Funnel plots with respect to standard errors (the line
in plot represents the regression line from metaregression): Iscador
versus no extra treatment.
QoL-associated variables is rather low (all studies <3).
Randomisation versus nonrandomisation was thus the main
relevant variable used in the multivariable metaregression
analyses which showed that randomized studies did not
diﬀer from non-randomized investigations.
In all publications addressing the eﬀects of Iscador appli-
cation on QoL-associated variables positive eﬀects found;
however, the funnel plots may indicate either a selection
bias or a lack of equipoise (i.e., the investigators may have
justiﬁableassumptionsofdrugsuperiorityandthusintended
to prove the eﬀectiveness of the Iscador). Two-thirds of the
studies were from the same origin and thus had the same
methodological problems. These had a matched-pair design,
either with or without randomization, a good description
of the methodology, and a profound discussion of potential
bias factors. It is obvious that the strict matching process
signiﬁcantly aﬀected the number of patients enrolled in
the evaluation (all studies had had sample sizes of <200
subjects), but it is diﬃcult to explain the data of the funnel
plots which indicate a publication bias in favor of positive
results.
4.2. Congruence of Results. Although the beneﬁt of adju-
vant mistletoe treatment has been demonstrated in some
randomized and observational studies, a comprehensive
meta-analytical approach like the present one has not been
previously conducted. Ernst et al. published a systematic
review on randomized clinical trials (RCTs) using various
VA-Es and stated that “statistical pooling was not possible
becauseoftheheterogeneityoftheprimary studies;therefore
a narrative systematic review was conducted” [11]. We could
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Figure 4: Funnel plots with total patient numbers (the line in plot
represents the regression line from metaregression): Iscador versus
no extra treatment.
conﬁrm the heterogeneity of investigations on the clinical
eﬀects of VA-E, but nevertheless were able to extract data
from several trials which provided enough data to calculate
SMDs and their standard errors. Ernst et al. stated that the
weakerstudiesimpliedbeneﬁtsofVA-E,particularlyinterms
ofqualityoflife,while noneofthemethodologicallystronger
studieswere abletoverifyabeneﬁtwith respect tosurvival or
QoL [11].
A Cochrane Review of Horneber et al. published in 2008
analyzed RCTs on various mistletoe extract preparations
and indicated weak evidence that VA-E application could
be eﬀective with respect to QoL during chemotherapy for
breastcancer[12].Bothgroups[11,12]arguedthatthemain
reason for the restricted informative value of the ﬁndings
concerning subjective outcomes in trials with VA-E was the
unblinded assessments or the unblinding of the intervention
through local reactions.
Also Kienle et al. summarized in their systematic review
of various RCTs from 2003 that most of these publications
reported statistically signiﬁcant positiveoutcomes(orat least
positive trends) for survival or tumor remission and QoL,
while several studies reported no eﬀect on survival, recur-
rence, remission, and QoL [6]. In 2007, Kienle and Kiene
published a systematic review of prospective clinical trials
on anthroposophic mistletoe extracts and stated beneﬁcial
eﬀectsofVA-EapplicationwithrespecttoQoLandreduction
of side eﬀects of cytoreductive therapies in most analyzed
trials [9]. They concluded that the best evidence for eﬃcacy
ofVA-EexistsfortheimprovementofQoLandthereduction
ofsideeﬀectsofcytotoxictherapies,whilethesurvivalbeneﬁt
was a matter of critique [9].6 Evidence-Based Complementary and Alternative Medicine
4.3. Limitations of the Used Measures of QoL and Associ-
ated Dimensions. To avoid a selection bias, we included
all studies addressing QoL-associated dimensions, that is,
studies using standard health-related OoL-instruments and
those measuring QoL related dimensions. We will discuss
putativelimitationsofsomeinstruments usedbytheprimary
authors.
The investigation of Kjaer, which used a less suited
visual analogue scale (VAS) to measure well-being and QoL,
was excluded from analysis anyway because the authors
presented just the data of the VA-E arm [35, 36]. The
investigation of Borelli [24] used the Spitzer Quality of Life
Index [37] which covers relevant 5 QoL dimensions. Also
the EORTC-QLQ C30 and BR 23 which incorporate 9 multi-
item scales is among the best ﬁtting QoL instruments [38].
The trial of Dold et al. [25]u s e dam e a s u r ew h i c hr e f e r st o
the Karnofsky performance status scale [39], which is the
physician’s rating of physical activity and self-supply, and
rated additional medical conditions such as appetite, cough,
dyspnea, pain, fever, and edema. These measures refer to
important aspects of QoL and can be regarded as more
or less suitable. However, this study relied on physician’s
rating rather than patient’s self-assessment; nevertheless, to
avoid a selection bias we decided to include this study too
(in fact the treatment eﬀects were rather low, and thus this
decision would not promote very positive overall eﬀects).
Theauthorsdetectedsigniﬁcant diﬀerencesonlywithrespect
to subjective improvement of disorders—but there were no
diﬀerencesbetween the groups with respect to the outcomes.
All other trials used a 16-item instrument to measure
psychosomatic “self-regulation” [26–33, 40], which was
assumed to asses an important aspect of QoL. Recently we
were able to approve correlations between “self-regulation”
and QoL; this unique dimension deals with competence
and autonomy of patients and thus should be regarded as
an active problem-solving capacity in terms of an active
adaptation to stressful situations to restore well-being [41].
Nevertheless, this dimension can be regarded as QoL associ-
ated.
4.4. PotentialBias Factors. Potential bias factors which might
contributetotheoverallpositiveeﬀectsdescribedintheanal-
ysesofGrossarth-Maticek etal.[26–33, 40] were discussed in
detail by the authors themselves [26, 29], that is, selection
bias and loose matching, Cox proportional hazard models
with/without adjustments, and so forth. Because these
studies started in 1973, several relevant study objectives were
not available, that is, exact dates of ﬁrst diagnosis, operation,
initial and follow-up data assessments and matching, socio-
economic status, social support, spirituality, and so forth. In
these studies, attrition bias was less important because with
the drop out of any study patient, the matching partner was
also excluded and thus the balance of the groups was not
severely aﬀected [26, 29]. Altogether, their internal validity
was limited by selection bias and confounding; moreover,
there were no written protocol, no statistical hypotheses, and
no sample size calculation, the sample sizes were in most
cases very small.
Patients expectations
Activity/adjustment
Tumor cell
apoptosis
Activation un-/speciﬁc
immune system
Beta-endorphin
release
Survival QoL
’ Viscum album application
Figure 5: Hypothetical diagram explaining the possible mecha-
nisms of Viscum album extract application on QoL.
Anotherintriguing factcouldbethatthenonrandomized
studies of Grossarth-Maticek’s group might have a lower
external validity (generalisability), because the inclusion and
exclusion criteria were not very precise and not all of them
were explicitly formulated in advance. Moreover, apart from
the matching criteria, there were no explicit procedures for
building pairs. The most important fact was raised by the
a u t h o r st h e m s e l v e s[ 26, 29, 33], as they cannot exclude
the possibility that patients with a good prognosis were
preferentially enrolled, since patients from both groups who
died shortly after the diagnosis would not have entered the
study.
Because the investigations with a stronger internal valid-
ity yielded similar results as compared to the studies with
the stronger external validity point in the same direction,
one can conclude that the results are more or less consistent.
Nevertheless, because severalpatients started with lower self-
regulation score during the treatment, one cannot exclude
the possibility of normalization and regression to the mean
eﬀects.
4.5. Explanation of Outcome Eﬀects. How could the positive
eﬀects of Iscador on QoL-related dimensions be explained
(Figure 5)? Direct pharmacological eﬀect could depend on
the applied doses, as suggested by N´ emeth et al. [42].
Indeed, a recent study investigated diﬀerent doses escala-
tion regimes of Iscador and found signiﬁcant diﬀerences
for the QoL aspects: physical complaints, vitality, mental
behavior, presence of personality, and social environment
[43]; particularly the presence of personality was highest
in the group with large local reactions in response to the
plant extract, an eﬀect which was signiﬁcantly dependent
on the dose escalation. That the plant extract by itself may
be crucial for the beneﬁcial eﬀects is supported by ﬁndings
showing that the survival of cancer patients is a function of
the relative duration of Iscador treatment, even in patients
with initially identical “self-regulation” scores [26]. But it
is unclear whether the physical improvement may precede
a psychical stabilization or whether a mental stabilization
may have a stress-reducing eﬀect which in turn may have a
beneﬁcial eﬀect on the physical situation.
One cannot ignore the fact that positive expectations of
the patients are also modulating factors inﬂuencing behavior
which in turn can have a strong impact on health. Expec-
tations are also thought to underlie the so-called “placeboEvidence-Based Complementary and Alternative Medicine 7
eﬀects”, impacting perceptions and biological processes. In
fact, invasive procedures such as injections have a higher
“placebo response” compared with oral drugs [44]. One
should realize that the “placebo eﬀect”itself represents a true
measurablecorrelateofanorganism’s psychoneurobiological
response and, thereby, inﬂuences the healing process [45].
The “placebo eﬀect” is taken to mean also the broad array
of nonspeciﬁc eﬀects in the patient-physician relationship,
includingattention,compassionate care,andthemodulation
of expectations; anxiety; self-awareness [46]. At least, one
may suggest that all of these explanations could contribute
t ot h eo b s e r v e dp o s i t i v ee ﬀects, particularly because the
application of VA-E is regarded by most patients as an active
and eﬀective chance to ﬁght the tumor. Thus, there might be
a combination of pharmacological and motivational aspects
mediated by the Iscador application which may contribute
t ot h ep o s i t i v eo u t c o m e( Figure 5). Whatever the underlying
eﬀects are, a recent review of our group found that pooled
analysis ofclinicalstudiessuggeststhatadjuvanttreatmentof
cancerpatientswiththemistletoeextractIscador isassociated
with a better survival [13], albeit we found hints for a
publication bias which limits the evidence found in that
meta-analysis, and this better survival is probably associated
with a better QoL, too.
5.Conclusion
The analyzed trials givesome evidencethatIscador treatment
might have moderate beneﬁcial short-time eﬀects on QoL-
associated dimensions and psychosomatic self regulation.
We are aware that the pooled estimates are driven by
quite heterogeneous data. Because the results are promis-
ing, despite of methodological limitations, large and well-
designed randomized controlled trials should be funded.
Subsequently, the studies may serve as models for future
trials in the area.
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